SCHEMBL8428624

SCHEMBL8428624

Cc1cn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)Oc3ccc([N+](=O)[O-])cc3)O2)c(=O)[nH]c1=O

nearest known ligand 0.68

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TYMS P04818 4/20 0.68
POLB P06746 1/20 0.61
TK1 P04183 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3063249 1.00 TYMS (0.68) TYMSPOLBTK1
Ammonia Solution, Strong SCHEMBL8170309 0.99 TYMS (0.67) TYMSPOLBTK1
SCHEMBL2057388 0.95 TYMS (0.64) TYMSPOLBTK1
SCHEMBL20582548 0.92 TYMS (0.63) TYMSPOLBTK1
SCHEMBL11587776 0.91 TYMS (0.65) TYMSPOLBTK1
SCHEMBL21003255 0.91 TYMS (0.65) TYMSPOLBTK1
SCHEMBL5832481 0.91 TYMS (0.60) TYMSPOLBTK1
SCHEMBL5832477 0.91 TYMS (0.60) TYMSPOLBTK1
SCHEMBL8170305 0.90 TYMS (0.63) TYMSPOLBTK1
Doxribtimine SCHEMBL20797965 0.88 TYMS (0.63) TYMSPOLBTK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049294-A1 ENPP1 Polypeptides and Methods of Using Same UNIV YALE (US) 2026-02-19 US disclosed
US-20260022356-A1 NPP1 Fusion Proteins INOZYME PHARMA INC (US) 2026-01-22 US disclosed
US-20250230423-A1 ENPP1 POLYPEPTIDES AND METHODS OF USING SAME UNIV YALE (US) 2025-07-17 US disclosed
US-12344868-B2 ENPP1 polypeptides and methods of using same YALE UNIVERSITY (US) 2025-07-01 US disclosed
US-20250115609-A1 AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF INNOVSTONE THERAPEUTICS LIMITED (CN) 2025-04-10 US disclosed
EP-4450503-A1 AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF Innovstone Therapeutics Limited (CN) 2024-10-23 EP disclosed
CN-117883449-A ENPP1 inhibitors and their use for the treatment of cancer 里兰斯坦福初级大学理事会 2024-04-16 CN disclosed
CN-111372587-B ENPP1 inhibitors and their use for the treatment of cancer 里兰斯坦福初级大学理事会 2024-01-09 CN disclosed
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2023-06-15 US disclosed
US-20230129977-A1 NPP1 FUSION PROTEINS BIOMARIN PHARMACEUTICAL INC. 2023-04-27 US disclosed
CN-113677350-A ENPP1 inhibitors and methods of modulating immune responses 里兰斯坦福初级大学理事会 2021-11-19 CN disclosed
EP-3844280-A1 ENPP1 POLYPEPTIDES AND METHODS OF USING SAME Yale University (US) 2021-07-07 EP disclosed
WO-2021053507-A1 2-AMINO-S6-SUBSTITUTED THIOPURINE COMPOUNDS AS INHIBITORS OF THE ENPP1 PROTEIN ATEN PORUS LIFESCIENCES PVT. LTD. (IN) 2021-03-25 WO disclosed
WO-2020212995-A1 HIGHLY SELECTIVE AND POTENT NPP1 INHIBITORS BASED ON URIDINE-5'-P,-DITHIOPHOSPHATE ANALOGUES BAR-ILAN UNIVERSITY (IL) 2020-10-22 WO disclosed
WO-2020206302-A1 ENPP1 POLYPEPTIDES AND METHODS OF USING SAME YALE UNIVERSITY (US) 2020-10-08 WO disclosed
CN-111372587-A ENPP1 inhibitors and their use for treating cancer 里兰斯坦福初级大学理事会 2020-07-03 CN disclosed
WO-2020047520-A1 ENPP1 POLYPEPTIDES AND METHODS OF USING SAME YALE UNIVERSITY (US) 2020-03-05 WO disclosed
US-20140378408-A1 NUCLEOSIDE 5'-PHOSPHOROTHIOATE ANALOGUES AND USES THEREOF BAR ILAN UNIVERSITY AN ISRAELI UNIVERSITY (IL) 2014-12-25 US disclosed
WO-2013132489-A1 NUCLEOSIDE 5'-PHOSPHOROTHIOATE ANALOGUES AND USES THEREOF BAR-ILAN UNIVERSITY (IL) 2013-09-12 WO disclosed
US-5962291-A MONOCLONAL ANTIBODY CAPABLE OF HYDROLYZING A SUBSTRATE; HAS TWO BINDING SITES: ONE FOR FREE METAL ION, ONE FOR SUBSTRATE THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 1999-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378408-A1 NUCLEOSIDE 5'-PHOSPHOROTHIOATE ANALOGUES AND USES THEREOF CCL2, NUDT1, CXCL12 TYMS 100/4885POLB 693/4885TK1 88/4885
US-20260049294-A1 ENPP1 Polypeptides and Methods of Using Same ENPP1, ENPP3, PNP TYMS 713/4885POLB 945/4885TK1 463/4885
US-20260022356-A1 NPP1 Fusion Proteins SPPL2B, LNPEP, CPN1 TYMS 1737/4885POLB 2525/4885TK1 249/4885
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, STING1 TYMS 256/4885POLB 392/4885TK1 143/4885
US-20250115609-A1 AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF ENPP1, WEE1, ENPP2 TYMS 175/4885POLB 3807/4885TK1 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.